Biogen-UPenn Alliance Announced

Less than 2 years after inception, the Center for Advanced Retinal and Ocular Therapeutics (CAROT) and University of Pennsylvania Perelman School of Medicine have struck a deal with Biogen to expand its work on ocular gene therapy. The deal will fund programs on two disease targets through preclinical development and Phase I clinical trials.

WELCOME!

Welcome to the Center for Advanced Retinal and Ophthalmic Therapeutics! Our mission is to advance the development of novel biologic and small molecule therapeutics for retinal and ocular diseases through a balanced commitment to basic research, translational development, and the clinician/patient communities. With a solid foundation in clinically relevant ocular research, CAROT will position itself as a global premiere center for translating novel bench research, such as gene and cell therapies, into the clinics and the market. The center will strive to foster nascent projects through various stages of clinical development. We aim to establish an efficient and effective translational infrastructure and a supportive environment for both academic and commercial communities.

The Center for Advanced Retinal and Ocular Therapeutics, or CAROT, is advancing the development of novel biologic and small molecule therapeutics for retinal and ocular diseases through a balanced commitment to basic research, translational development, and the clinician/patient communities.